(ARQT) Arcutis Biotherapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.505m USD | Total Return: 52.7% in 12m

Topical Creams, Therapeutic Foams, Fusion Proteins, Dermatological Drugs
Total Rating 45
Safety 38
Buy Signal -0.93
Biotechnology
Industry Rotation: -8.2
Market Cap: 2.51B
Avg Turnover: 33.2M
Risk 3d forecast
Volatility65.3%
VaR 5th Pctl10.5%
VaR vs Median-2.45%
Reward TTM
Sharpe Ratio0.94
Rel. Str. IBD34.9
Rel. Str. Peer Group24.8
Character TTM
Beta0.873
Beta Downside0.647
Hurst Exponent0.405
Drawdowns 3y
Max DD83.24%
CAGR/Max DD0.43
CAGR/Mean DD1.54
EPS (Earnings per Share) EPS (Earnings per Share) of ARQT over the last years for every Quarter: "2021-03": -0.76, "2021-06": -0.84, "2021-09": -1.14, "2021-12": -1.42, "2022-03": -1.27, "2022-06": -1.31, "2022-09": -1.89, "2022-12": -1.18, "2023-03": -1.31, "2023-06": -1.16, "2023-09": -0.73, "2023-12": -0.72, "2024-03": -0.32, "2024-06": -0.42, "2024-09": -0.33, "2024-12": -0.09, "2025-03": -0.2, "2025-06": -0.13, "2025-09": 0.06, "2025-12": 0.13, "2026-03": -0.09,
Last SUE: -0.39
Qual. Beats: 0
Revenue Revenue of ARQT over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0.725, 2022-12: 2.961, 2023-03: 2.781, 2023-06: 5.19, 2023-09: 38.109, 2023-12: 13.526, 2024-03: 49.569, 2024-06: 30.858, 2024-09: 44.755, 2024-12: 71.36, 2025-03: 65.846, 2025-06: 81.504, 2025-09: 99.219, 2025-12: 129.503, 2026-03: 105.398,
Rev. CAGR: 188.19%
Rev. Trend: 92.9%
Last SUE: 0.13
Qual. Beats: 0

Warnings

Interest Coverage Ratio 0.7 is critical

Altman Z'' -8.53 < 1.0 - financial distress zone

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: ARQT Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc. (ARQT) is a California-based biopharmaceutical company specializing in the development and commercialization of topical therapies for inflammatory dermatological conditions. The company’s primary product portfolio is centered on ZORYVE (roflumilast), a topical PDE4 inhibitor currently utilized for plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Additionally, the firm is advancing ARQ-234, a CD200 receptor checkpoint agonist, to target systemic immune-mediated diseases.

The biotechnology sector often requires heavy capital investment in the research and development phase before achieving commercial profitability. Arcutis utilizes a business model focused on medical dermatology, targeting high-prevalence skin diseases where unmet needs exist for non-steroidal, long-term treatment options. Investors should examine ValueRay to further evaluate the companys valuation metrics and pipeline potential. This specialized focus allows the company to leverage a single active ingredient across multiple delivery formats, such as creams and foams, to address various body sites and patient preferences.

Headlines to Watch Out For
  • ZORYVE cream prescription volume growth in plaque psoriasis and atopic dermatitis markets
  • FDA approval and commercial launch of ZORYVE foam for seborrheic dermatitis
  • Payer coverage expansion and net price realization for topical roflumilast products
  • R&D expenditure and cash burn rate impacting future equity financing needs
  • Competitive dynamics within the topical JAK inhibitor and biologic dermatology landscape
Piotroski VR-10 (Strict) 6.0
Net Income: -2.38m TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA 39.76 > 1.0
NWC/Revenue: 66.13% < 20% (prev 109.3%; Δ -43.14% < -1%)
CFO/TA 0.06 > 3% & CFO 27.0m > Net Income -2.38m
Net Debt (-102.8m) to EBITDA (12.8m): -8.05 < 3
Current Ratio: 2.68 > 1.5 & < 3
Outstanding Shares: last quarter (129.4m) vs 12m ago 2.64% < -2%
Gross Margin: 90.94% > 18% (prev 0.88%; Δ 9.01k% > 0.5%)
Asset Turnover: 103.4% > 50% (prev 61.85%; Δ 41.53% > 0%)
Interest Coverage Ratio: 0.73 > 6 (EBITDA TTM 12.8m / Interest Expense TTM 13.5m)
Altman Z'' -8.53
A: 0.60 (Total Current Assets 438.1m - Total Current Liabilities 163.2m) / Total Assets 460.0m
B: -2.50 (Retained Earnings -1.15b / Total Assets 460.0m)
C: 0.02 (EBIT TTM 9.82m / Avg Total Assets 402.1m)
D: -4.25 (Book Value of Equity -1.15b / Total Liabilities 270.4m)
Altman-Z'' = -8.53 = D
Beneish M -2.71
DSRI: 0.87 (Receivables 144.4m/85.4m, Revenue 415.6m/212.8m)
GMI: 0.97 (GM 90.94% / 88.39%)
AQI: 0.72 (AQ_t 0.04 / AQ_t-1 0.05)
SGI: 1.95 (Revenue 415.6m / 212.8m)
TATA: -0.06 (NI -2.38m - CFO 27.0m) / TA 460.0m)
Beneish M = -2.71 (Cap -4..+1) = A
What is the price of ARQT shares?

As of May 24, 2026, the stock is trading at USD 20.86 with a total of 1,063,194 shares traded.
Over the past week, the price has changed by -2.16%, over one month by -12.17%, over three months by -20.71% and over the past year by +52.71%.

Is ARQT a buy, sell or hold?

Arcutis Biotherapeutics has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy ARQT.

  • StrongBuy: 4
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ARQT price?
Analysts Target Price 34.6 66%
Arcutis Biotherapeutics (ARQT) - Fundamental Data Overview as of 20 May 2026
P/E Forward = 111.1111
P/S = 6.0281
P/B = 13.2109
Revenue TTM = 415.6m USD
EBIT TTM = 9.82m USD
EBITDA TTM = 12.8m USD
Long Term Debt = 108.0m USD (from longTermDebt, last fiscal year)
Short Term Debt = 7.95m USD (from shortTermDebt, last quarter)
Debt = 121.2m USD (corrected: LT Debt 108.0m + ST Debt 7.95m) + Leases 5.27m
Net Debt = -102.8m USD (calculated: Debt 121.2m - CCE 224.0m)
Enterprise Value = 2.40b USD (2.51b + Debt 121.2m - CCE 224.0m)
Interest Coverage Ratio = 0.73 (Ebit TTM 9.82m / Interest Expense TTM 13.5m)
EV/FCF = 89.26x (Enterprise Value 2.40b / FCF TTM 26.9m)
FCF Yield = 1.12% (FCF TTM 26.9m / Enterprise Value 2.40b)
FCF Margin = 6.48% (FCF TTM 26.9m / Revenue TTM 415.6m)
Net Margin = -0.57% (Net Income TTM -2.38m / Revenue TTM 415.6m)
Gross Margin = 90.94% ((Revenue TTM 415.6m - Cost of Revenue TTM 37.6m) / Revenue TTM)
Gross Margin QoQ = 90.72% (prev 90.97%)
Tobins Q-Ratio = 5.22 (Enterprise Value 2.40b / Total Assets 460.0m)
Interest Expense / Debt = 11.12% (Interest Expense 13.5m / Debt 121.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = 7.76m (EBIT 9.82m * (1 - 21.00%))
Current Ratio = 2.68 (Total Current Assets 438.1m / Total Current Liabilities 163.2m)
Debt / Equity = 0.64 (Debt 121.2m / totalStockholderEquity, last quarter 189.6m)
Debt / EBITDA = -8.05 (Net Debt -102.8m / EBITDA 12.8m)
Debt / FCF = -3.82 (Net Debt -102.8m / FCF TTM 26.9m)
Total Stockholder Equity = 169.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.59% (Net Income -2.38m / Total Assets 460.0m)
RoE = -0.18% (Net Income TTM -2.38m / Total Stockholder Equity 1.32b)
RoCE = 0.69% (EBIT 9.82m / Capital Employed (Equity 1.32b + L.T.Debt 108.0m))
RoIC = 2.55% (NOPAT 7.76m / Invested Capital 304.7m)
WACC = 9.04% (E(2.51b)/V(2.63b) * Re(9.05%) + D(121.2m)/V(2.63b) * Rd(11.12%) * (1-Tc(0.21)))
Discount Rate = 9.05% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.22 | Cagr: 16.03%
[DCF] Terminal Value 73.06% ; FCFF base≈26.9m ; Y1≈27.0m ; Y5≈28.6m
[DCF] Fair Price = 4.01 (EV 398.6m - Net Debt -102.8m = Equity 501.5m / Shares 125.1m; r=9.04% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.39 | # QB: 0
Revenue Correlation: 92.93 | Revenue CAGR: 188.2% | SUE: 0.13 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.05 | Chg30d=-28.15% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=0.09 | Chg30d=-35.80% | Revisions=-14% | Analysts=5
EPS current Year (2026-12-31): EPS=0.24 | Chg30d=-33.26% | Revisions=-14% | GrowthEPS=+288.5% | GrowthRev=+32.2%
EPS next Year (2027-12-31): EPS=1.16 | Chg30d=-9.61% | Revisions=-43% | GrowthEPS=+371.7% | GrowthRev=+29.9%
[Analyst] Revisions Ratio: -43%